Bruce Carter

Dr. Bruce Carter is a c-level executive and board director with experience in American, European, and Asian companies in both the public and private sectors. Dr. Carter serves as a Senior Advisor to Accelerator and Chairman of the Board to ALSP Orchid Acquisition Corporation I (NASDAQ: ALORU | ALOR). Prior to his role at Accelerator, Dr. Carter was the Chairman of the Board and former Chief Executive Officer of ZymoGenetics Inc., USA.

He has also served as the Corporate Executive Vice President and Chief Scientific Officer for Novo Nordisk A/S, the former parent company of ZymoGenetics. From 1982 to 1986, Dr. Carter held various positions of increasing responsibility at G.D. Searle & Co., Limited, including Head of Molecular Genetics. He was a lecturer at Trinity College, University of Dublin, from 1975 to 1982. Dr. Carter holds directorship in Enanta Pharmaceutical, Mirati Therapeutics, Accelerator IV-Seattle Corporation, TB Alliance, Aurigene Discovery Technologies Limited (India), and Dr. Reddy’s Laboratories (U.S.).

Dr. Carter received his B.S. with Honors in Botany from the University of Nottingham, England and his Ph.D. in Microbiology from Queen Elizabeth College, London University, UK.